Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients developing or developed acute or chronic GVHD within the last 10 days which require systemic immunosuppressive therapy of corticosteroids with- or-without other immunosuppressive agents including calcineurin inhibitors.~  1. acute GVHD, grade 2-4~ 2. chronic GVHD, mild grade with high risk or moderate to severe grade~* Written informed consent form~Exclusion Criteria:~* Aspartate transaminase or alanine transaminase level \> 10 times UNL or Bilirubin or alkaline phosphatase level \> 5 times UNL~* Active or chronic hepatitis virus B or C infection requiring antiviral therapy~* Estimated life expectancy \< 30 days~* History of allergy, sensitivity, or any serious reaction to itraconazole oral solution~* Previous history of Zygomycosis~* Evidence of active fungal disease including high galactomannan titer above 0.5, within 2 weeks.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- itraconazole, prophylaxis, Oral solution (Type: EXPERIMENTAL): For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).